Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCibus Global LLC

Cibus Global LLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.145 USD -0.01 ( 0.43%)
Last update at 2026-11-10T21:01:00Z
VOLUME
177086
Market Cap
120.58M

Momentum Score

…

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.07
Low
1.27
High
52 Week Price Range
1.09
Low
4.19
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for Cibus Global LLC (NASDAQ: CBUS) are limited, preventing a clear, independently verifiable description of its core business from available public sources. Long-term growth may depend on successful execution of its stated business plan, access to capital, and favorable market or regulatory conditions; investors may find appeal in potential upside if management executes and market demand materializes.

Material risks include limited public disclosure and low liquidity, execution and financing risk, and potential regulatory or market-acceptance challenges; investors should monitor SEC filings, management updates, and trading volume.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.15
Dividend Yield
-
Revenue TTM
3.64M
Revenue Per Share
0.08
Gross Profit TTM
3.64M
Debt / Equity
12.28
ROE
-220.96%
Net Debt
258.04M
ROCE
-23.41%
Diluted EPS TTM
-2.78

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -132.17M -282.68M -337.64M -16.89M -29.20M
Minority interest 5.12M 31.32M 70.01M - -
Net income -127.08M -251.39M -267.63M -16.89M -29.20M
Selling general administrative 26.91M 30.80M 23.14M 10.97M 15.38M
Gross profit -2.28M 4.26M 1.42M 0.16M -2.57M
Reconciled depreciation 5.92M 6.86M 3.25M 1.53M 2.34M
Ebit -67.46M -248.49M -319.28M -23.90M -30.86M
Ebitda -61.54M -241.63M -314.58M -22.37M -28.52M
Depreciation and amortization 5.92M 6.86M 4.69M 1.53M 2.34M
Operating income -67.46M -258.40M -318.88M -22.37M -29.33M
Other operating expenses 71.10M 262.66M 320.70M 22.53M 55.32M
Interest expense 35.48M 34.19M 18.89M 0.07M 1.43M
Tax provision 0.03M 0.03M -0.00M 0.00M 0.00M
Interest income 0.44M 0.63M 0.53M 0.06M 0.02M
Net interest income -35.04M -33.56M -10.40M -0.09M -1.41M
Income tax expense 0.03M 0.03M -0.00M -1.45M -0.11M
Total revenue 3.64M 4.26M 1.82M 0.16M 25.99M
Total operating expenses 65.18M 262.66M 320.31M 22.53M 26.76M
Cost of revenue 5.92M 6.86M 0.40M 0.00M 28.56M
Total other income expense net -64.71M -24.29M -18.76M 5.57M 1.55M
Net income from continuing ops -132.20M -282.71M -63.27M -16.89M -29.20M
Net income applicable to common shares - - - -16.89M -29.20M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 305.05M 350.07M 544.41M 22.42M 37.19M
Intangible assets 31.68M 33.58M 35.41M - -
Other current assets 1.44M 1.47M 1.99M 0.61M 0.86M
Total liab 283.22M 252.24M 206.12M 15.19M 23.06M
Total stockholder equity 21.83M 97.83M 293.47M 7.23M 14.13M
Other current liab 5.09M 8.15M 7.04M 1.23M 3.22M
Common stock 0.08M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -858.25M -731.17M -479.78M -212.15M -196.09M
Other liab - - - 0.08M 0.70M
Good will 232.52M 253.47M 434.90M - -
Other assets - - - 0.16M 0.28M
Cash 9.92M 14.43M 32.70M 3.43M 13.82M
Total current liabilities 16.86M 19.88M 21.32M 1.66M 4.85M
Current deferred revenue 0.54M 0.93M 1.21M 0.46M 3.03M
Net debt 258.04M 21.85M -8.08M 10.12M 4.05M
Short term debt 3.17M 0.44M 6.95M 0.10M 0.37M
Short long term debt 0.43M 0.44M 0.83M - -
Short long term debt total 267.96M 36.29M 24.62M 13.54M 17.88M
Other stockholder equity 880.03M 823.30M 771.82M 219.38M 210.22M
Property plant equipment - - - 18.13M 21.73M
Total current assets 12.07M 16.95M 35.22M 4.13M 15.18M
Net tangible assets - - - 7.23M 14.13M
Short term investments - - - - 0.00M
Net receivables 0.70M 1.04M 0.53M - 0.00M
Long term debt 0.09M 0.23M 0.54M - -
Inventory - - - - 0.00M
Accounts payable 8.07M 5.96M 6.13M 0.34M 1.26M
Accumulated other comprehensive income 0.04M 0.01M 0.01M - -
Non currrent assets other 0.93M 1.39M 1.42M 0.16M 0.28M
Non current assets total 292.98M 333.12M 509.19M 18.29M 22.01M
Capital lease obligations 32.51M 35.62M 23.25M 13.54M 17.88M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.81M 55.50M -1.52M 11.20M
Change to liabilities - - - -0.23M -0.36M
Total cashflows from investing activities -0.58M -0.81M 55.06M -1.52M 11.20M
Net borrowings -1.11M -0.88M 2.31M -0.38M -0.36M
Total cash from financing activities 46.65M 40.60M 20.32M 9.99M 3.74M
Change to operating activities - - - -2.66M 1.58M
Net income -127.08M -282.71M -267.63M -16.89M -29.20M
Change in cash -4.51M -18.27M 29.17M -10.89M -3.87M
Begin period cash flow 14.43M 32.70M 3.53M 14.42M 18.29M
End period cash flow 9.92M 14.43M 32.70M 3.53M 14.42M
Total cash from operating activities -50.59M -58.04M -46.21M -19.36M -18.81M
Issuance of capital stock 50.10M 43.90M 0.33M 11.54M 4.38M
Depreciation 5.92M 6.86M 4.69M 1.53M 2.34M
Change to inventory - - -0.92M 0.00M 1.38M
Change to account receivables 0.54M -0.51M 1.70M 0.00M 4.89M
Other cashflows from financing activities -0.14M -2.42M 1.76M -1.17M -0.27M
Change to netincome - - - -1.12M 0.56M
Capital expenditures 0.58M 0.81M 4.32M 1.52M 0.50M
Change in working capital 2.32M 0.38M 0.96M -2.88M 7.49M
Stock based compensation 8.19M 10.75M 16.09M 4.00M 2.09M
Other non cash items 60.06M 206.68M 215.76M -5.12M -1.53M
Free cash flow -51.17M -58.85M -50.53M -20.88M -19.31M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CBUS
Cibus Global LLC		 -0.01
0.43%		 1.15 - - 33.14 5.46 39.11 -1.15
NVO
Novo Nordisk A/S		 -0.68
1.64%		 40.70 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.02
0.55%		 547.85 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -
-%		 916.06 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Cibus Global LLC

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

6455 Nancy Ridge Drive, San Diego, CA, United States, 92121

858 450 0008

https://www.cibus.com

118

Name Title Year Born
Mr. Rory Balfour Riggs M.B.A. Co-Founder, CEO & Chairman 1953
Dr. Peter Beetham B.Sc., Ph.D. Co-Founder, President, COO & Director 1963
Dr. Greg Gocal Ph.D. Co-Founder, Chief Scientific Officer & Executive VP 1969
Dr. Wade Hampton King Chief Financial Officer 1958
Mr. Jason Stokes J.D. Chief Legal Officer, General Counsel & Corporate Secretary NA
Ms. Rosa Cheuk Kim J.D. Senior Vice President of Legal NA
Dr. James Radtke Ph.D. Senior Vice President of Product Development NA
Mr. Tony Moran Senior Vice President of International Development NA
Norm Sissons Senior Vice President of Seed & Traits NA
Ms. Noel Sauer Ph.D. Senior Vice President of Research NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…